News

News

Media contact:

Clément Robijns | c.robijns@biocom.de | +49-30-264 921-58

New €19m JPIAMR call now open

Within the framework of the ERA-NET JPIAMR-ACTION, JPIAMR (Joint Programming Initiative on Antimicrobial Resistance) is launching…

A faster way to diagnose antibiotic resistance utilizing AI

As of recently, collaborative research between ETH Zürich, University Hospital Basel, and the University of Basel…

Early-stage ventures fighting AMR wanted!

Don’t miss to participate in the start-up competition @AMR conference supported by INCATE. Early-stage ventures fighting drug…

New pipeline report by WHO

The WHO has released a new report analyzing the current antibacterial pipeline. It has been published…

Employing supercomputers to fight antibiotic resistance

Approximately 700,000 people are estimated to die due to infection by antibiotic-resistant bacteria every year, with…

€9m funding for the multidisciplinary consortium ARPEGE

By combining preventive, diagnostic, therapeutic and economic approaches for the first time the ARPEGE consortium led…

Podcast episode on phage therapy with Dr. Richard Alm at CARB-X

CARB-X Chief Scientist Dr. Richard Alm joins host Steven Yang for this episode of The Phage…

Fighting AMR through rapid digital pandemic response

In December, a consortium of 8 public and 4 private Swiss institutions has joined forces to…

Interview with Rusudan Okujava, Roche

Pharma company Roche is among the partners of AMR-focused incubator INCATE. We spoke with Rusudan Okujava…

CARB-X surpasses all goals in first five years

With US$361 million awarded to 92 projects funding, CARB-X closed the fifth fiscal year since inception.…

FIND invests US$21m into molecular testing companies

In late December, FIND announced an investment of US$21 million to accelerate the development, manufacturing, and…

Ares Genetics to expand ARESdb proprietary contents

Diagnostics company Ares Genetics GmbH, developing NGS- and AI-powered solutions to combat AMR, has successfully completed…

G7 released new statement to support antibiotic development

The G7 Finance Ministers have released a statement on actions to support antibiotic development, with the goal…

BioNTFAO releases new 5-year Action Plan to combat AMR

The UN Food and Agriculture Organization BioNTFAO has issued an Action Plan spanning a total of…

The innovative life of SMEs

On the occasion of the World Antibiotic Awareness Week (WAAW), BEAM Alliance has published a series…

Interview with: Marc Gitzinger, BEAM Alliance & BioVersys

BEAM Alliance is among the partners of AMR-focused incubator INCATE. We spoke with Marc Gitzinger, CEO…

New report of animal health R&D funding patterns

Together with the International Development Research Center (IDRC), the Global AMR R&D Hub published a new…

Interview with: Philipp Müller, Boehringer Ingelheim Venture Fund

The Boehringer Ingelheim Venture Fund is among the industry partners of AMR-focused incubator INCATE. We spoke…

Interview with: Hideki Maki, Shionogi

The Japanese pharma company Shionogi is among the industry partners of AMR-focused incubator INCATE. We spoke…

BioNTech acquires Vienna-based start-up PhagoMed

BioNTech SE has acquired PhagoMed GmbH, an Austrian start-up for precision antimicrobial treatments supported by the…

PASTEUR Act re-introduced in US Senate

In mid-November, the AMR community welcomed the official introduction of Cures 2.0 by the bipartisan team of U.S.…

New €9m vaccine project to combat AMR with big data and AI

A new European consortia called PrIMAVeRA is developing an open-source, web-based platform combining mathematical models with…

Antibiotic Research UK to fund seven new research projects worth £200,000 in total

Antibiotic Research UK (ANTRUK) announced that through its 2021 Small Research Grants / Career Development Awards…

Analysis is estimating the appropriate size of global pull incentives

A new analysis published by Kevin Outterson in the Health Affairs journal is estimating the appropriate…

Session report: COVID-19 impact and lessons learned

AMR experts from Industry, SMEs, academia and public bodies discussed the impact of COVID-19 on AMR…

Session report: Updates on funds & accelerators

Investment climate for companies active in AMR was rather weak for a long time. However, over…

Session report: How to go ahead with pull incentives?

During the third day of the virtual 5th AMR Conference, the important role of governments and…

Pharma-backed start-up incubator launched

With INCATE a new public-private consortium was launched on 25 August to boost the development of…

How investors evaluate the AMR sector?

We spoke with Aleks Engel from the Novo Holdings Repair Impact Fund, one of the speakers…

Limited patient access to new antibacterials in high-income countries

A group of experts has shown in an analysis that also in high-income countries patient access…

Global AMR R&D Hub with new report

The Global AMR R&D Hub has published a report which highlights the mismatch between global needs…

CARB-X celebrates success in Europe

CARB-X is organizing a webinar to celebrate its European projects and funding partners which have supported…

Survey on AMR Multi-stakeholder Partnership Platform started

The Tripartite organizations (FAO, OIE, WHO) are conducting a public discussion survey on the development of…

£19.2 million for cross-government AMR surveillance project in UK

The British cross-departmental project team behind Pathogen Surveillance in Agriculture, Food and the Environment (PATH-SAFE) brings…

What antibiotics developers can learn from COVID-19 vaccine trials

British clinical trials expert Stephen Senn explains in a viewpoint essay on the GARDP website what…

The Global Fund grants US$37 million to FIND to advance tuberculosis prevention and control in India

FIND, the global alliance for diagnostics, and the Global Fund announced that FIND has been awarded…

New AMR research alliance tackling animal and human health

A new London-Liverpool research alliance in UK will bring together academic and commercial sectors in a…

New study finds variations in antibiotic consumption across Europe between 2014 and 2018

The European Centre for Disease Prevention and Control (ECDC) together with WHO Regional Office for Europe…

EU policymakers urged to consider AMR incentive models

In an EURACTIV report, policymakers across the EU are being urged to consider the full range…

Newly published guidance enables advances in testing for TB and drug resistance

FIND has contributed to two major documents recently published by the WHO that represent major advances…

New $60m mRNA vaccines programme by Wellcome Trust and CEPI

CEPI and Wellcome Trust have joined forces to further exploit the mRNA technology. To prepare for…

New collaboration between ICARS and the Global AMR R&D Hub

The Global AMR R&D Hub and ICARS announced a new partnership that will further strengthen their…

UNITE4TB launched under the umbrella of the IMI AMR Accelerator

A 7-year, €185 million project called UNITE4TB was started by 30 partners from 13 countries as…

JPIAMR’s Virtual Research Institute expands its digital platform to connect datasets

The JPIAMR’s Virtual Research Institute (JPIAMR-VRI) recently updated its digital platform to a large extent, now…

LSHTM partners with Johnson & Johnson

The London School of Hygiene & Tropical Medicine (LSHTM) has entered into a new partnership with…

Acurx Pharmaceuticals announces closing of initial public offering of common stock

Acurx Pharmaceuticals Incorporated, a clinical stage biopharmaceutical company committed to the development of a novel class…

Destiny Pharma and US Department of Veterans Affairs team up to fight Clostridioides difficile infections

Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company for the development of novel…

AMR Preparedness Index shows UK and US among best prepared

The Global Coalition on Aging (GCOA) together with the Infectious Diseases Society of America (IDSA) have…

Horizon Europe launches two new AMR-focused calls

The EU’s Research and Innovation funding programme, Horizon Europe, has launched its research calls for 2021-2022…

GW4 AMR Alliance to become the UK’s leading ‘One Health’ AMR research consortium

AMR is a complex, multi-faceted problem that affects all of society and is driven by many…

US Senate re-introduces PASTEUR Act

The US Senate has reintroduced the Pioneering Antimicrobial Subscriptions to End Up surging Resistance (PASTEUR) Act…

New BARDA Ventures will invest $500m to prepare for future health challenges

BARDA have announced the creation of a new venture to develop and commercialize technologies and medical…

EPSRC funds new programme ‘Beyond Antibiotics’

The 5-year programme will start in October 2021. Scientists from the Universities of Oxford, Ulster and…

Nanotherapeutics Hub joins forces with iiCON

The Nanotherapeutics hub and iiCON step up the UK’s infectious disease R&D pipeline. iiCON, led by…

Second financing for BioVersys from CARB-X

CARB-X is awarding BioVersys, a pharmaceutical company headquartered in Basel, Switzerland, up to US$4.35 million in…

GARDP and DNDi publish policy brief at 74th WHA

GARDP together with DNDi published a policy briefing statement at the 74th World Health Assembly. According…

Basilea supported by CARB-X funding

CARB-X is awarding Swiss listed company Basilea Pharmaceutica International up to US $2.7m to develop a novel class…

Sandoz is investing €150m in its antibiotics manufacturing setup in Europe

Sandoz, a Novartis division, has announced plans to invest €150m and further strengthen its European antibiotics…

CARB-X backs Summit Therapeutics with up to $4.1m

Up to $4.1 million in non-dilutive funding are being awarded by CARB-X to UK-based Summit Therapeutics. The capital…

BARDA seeks proposals for new Antibacterial Accelerator

BARDA is seeking proposals for a new Antibacterial Accelerator which is funded for the next ten…

High-level Interactive Dialogue on AMR

End of April the General Assembly High-Level Interactive Dialogue on Tackling AMR took place as a…

Pfizer grows infectious disease pipeline

US pharma company Pfizer acquired US-based biotech company Amplyx Pharmaceuticals for an undisclosed sum. The deal…

Diagnostics company GenomeKey funded by CARB-X

CARB-X is awarding GenomeKey (Genomics Labs Ltd.) in Bristol, UK, up to $3.0 million in non-dilutive…

X-Biotix stops antibacterial activities

US-based X-Biotix Therapeutics, focused on antibiotic compounds targeting multi-drug-resistant Gram-negative pathogens, will suspend its current antibacterial…

Bacteriophage-company Pico Therapeutics backed by CARB-X

CARB-X is funding Phico Therapeutics, in Cambridge, UK, to develop a new intravenous engineered bacteriophage drug…

Update on WHO pipeline report available

The WHO has published their updated analysis for the clinical and preclinical antibacterial product pipeline in…

BioVersys gets €20m EIB loan to develop novel antibiotics

Swiss BioVersys has received €20m from the European Investment Bank to push the development of new…

EU starts consultation process on HERA

The European Commission launched an online public consultation on the Health Emergency Preparedness and Response Authority…

University of Oxford receives funding

CARB-X is awarding up to US$2 million to the Jenner Institute, part of the University of…

Guidance on Stewardship and Access for developers published

Led by Wellcome Trust, a group of AMR funders has published the first guidance on strategies…

New study on national policy options

The Global AMR R&D Hub has published a study on national policy options to reward the…

GSK receives up to $18m CARB-X funding for two vaccine projects

CARB-X is funding the GSK Biologicals and its affiliate GSK Vaccines Institute for Global Health (GVGH),…

French biotech Mutabilis funded by CARB-X

CARB-X is awarding Mutabilis, a biopharmaceutical firm based in Romainville, France, up to US$6.4 million to…

CARB-X will invest up to US$15m for German AMR projects

CARB-X announced the investment of first grants to two German research teams from the German Helmholtz…

CARB-X is funding a team of top German researchers to develop a drug to treat Staphylococcus aureus infections and prevent exacerbation of life-threatening pneumonia

Researchers from the Helmholtz Centre for Infection Research (HZI) and the Lead Discovery Center GmbH (LDC)…

CARB-X is funding a German team of scientists to develop a new treatment for difficult-to-treat Pseudomonas aeruginosa infections in cystic fibrosis patients

Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) team could receive up to US$6.31 million if all…

Juvabis Announces Positive Phase 1 Results of EBL-1003 in the Innovative Medicines Initiative’s ENABLE Consortium

Single intravenous dose Phase 1 study in healthy volunteers showed that EBL-1003 (apramycin) was safe and…

World leaders join forces to fight the accelerating crisis of antimicrobial resistance

High-level global leaders group will advocate for urgent action to combat antimicrobial resistance across all sectors…

First Dynamic Dashboard analysis report and recommendations to the G20

The Global AMR R&D Hub publishes its first report “The state of public and philanthropic investments…

2020 Antimicrobial Resistance campaign: How to change the fight against AMR?

The BEAM Alliance recently worked with Global Cause on the 2020 Antimicrobial Resistance campaign. The content…

BioVersys starts Phase 1 Clinical Trial of BV100

BV100 is being developed for the treatment of serious hospital infections caused by Carbapenem resistant Acinetobacter baumannii…

CARB-X is funding Polyphor to develop a new antibiotic to treat multidrug-resistant Enterobacteriaceae Gram-negative bacterial infections

CARB-X announced today it is awarding up to US$2.62 million to Polyphor AG (SIX:POLN), headquartered in…

The Pharmaceutical Strategy is a chance to tackle antimicrobial resistance that Europe cannot miss says the MEP Interest Group on AMR

On 6 October, the MEP interest group on AMR released an official letter to the EU…

CARB-X funds GSK to develop a new drug for urinary tract infections (UTI) caused by Escherichia coli bacteria

CARB-X announced today it is awarding up to US$7.51 million to GlaxoSmithKline (NYSE: GSK), to develop…

Conference summary: Push for pull incentives

With around 450 attendees, the five-day digital conference particularly focused on market conditions and financing. SMEs…

Bioversys bags €17.7m financing

Swiss BioVersys AG has secured a CHF19m Series B financing to push clinincal development of two…

Start-up pitch winner: FluoretiQ

British diagnostics company FluoretiQ Ltd was selected as start-up pitch winner during the 4th annual AMR…

BEAM Alliance and global partners call for urgent action on new reimbursement models for life-saving antibiotics

BEAM Alliance and global partners call for urgent action on new reimbursement models for life-saving antibiotics…

What Can Be Learned From COVID-19 to Prevent the Next Health Emergency

Dr Manica Balasegaram, GARDP Executive Director, spoke at the opening of BIOCOM’s 4th AMR Conference on…

Aicuris to launch AiCubator to fight AMR

Antinfectives specialist AiCuris GmbH will launch the “AiCubator”, a new way to collaborate in anti-infectives and…

CARB-X is funding Evotec to develop a new class of broad-spectrum antibiotics

Evotec is the first pharmaceutical R&D company based in Germany in the CARB-X portfolio CARB-X announced…

Cost-efficient and green manufacturing of peptides thanks to Molecular Hiving technology™

Bachem and Jitsubo CO., LTD. recently announced the signature of an exclusive Licensing Agreement for Jitsubo’s…

PBS News Hour story Part II covers recent developments in the AMR field

A remarkable 2-part PBS News Hour story exclusively dedicated to AMR The antibiotics industry has suffered…

COVID-19 and AMR: Part I of the PBS News Hour story reflects the implications of the virus on AMR

A remarkable 2-part PBS News Hour story exclusively dedicated to AMR COVID-19 can be accompanied by…

Spanish vaccine company Vaxdyn receives CARB-X funding

CARB-X is funding Spanish biotech Vaxdyn to develop a new vaccine to prevent infections that cause…

AMR Action Fund: A $1b down payment from Industry

The AMR Action Fund expects to invest more than US$1 billion in smaller biotech companies and…

CARB-X funds Eligo Bioscience to develop CRISPR-based therapeutics

With a unique approach, Eligo engineers natural predators of bacteria to deliver CRISPR systems that kill…

Pharma giants return to antibiotics huddle to launch $1B venture fund

Big Pharma exited from the antibiotics space one by one – and now they may be…

How data partnerships can help tackle drug-resistant infections

Access to surveillance data crucial to tackling infectious diseases Wellcome Trust has partnered with Pfizer Inc.…

First Australian project in the CARB-X portfolio

CARB-X is awarding up to US$3.83 million to The University of Queensland’s Institute for Molecular Bioscience,…